Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > I'm in

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Mar 02, 2021 6:33pm

125 Views

Post# 32698523

RE:I'm in

Glad I sold today. Thought about holding until they release their 4th Q & Annual financials as the year 2020 will look good.

Problem comes in 1st Q when they book a $7 million plus (cdn. dollars) profit & loss entry. It could be more if the award in Bausch's favour stipulates more payments before the end of March.

It won't be pretty.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?